About Curetis
Curetis is a company based in Holzgerlingen (Germany) founded in 2007 was acquired by OpGen in September 2019. Curetis has raised $127.14 million across 14 funding rounds from investors including Qiagen, OpGen and European Investment Bank. The company has 55 employees as of December 31, 2020. Curetis offers products and services including Unyvero and Unyvero A50 Solution. Curetis operates in a competitive market with competitors including Prenetics, Inflammatix, Karius, Day Zero Diagnostics and MeMed, among others.
- Headquarter Holzgerlingen, Germany
- Employees 55 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Curetis Gmbh.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Curetis
Curetis offers a comprehensive portfolio of products and services, including Unyvero and Unyvero A50 Solution.
Rapid molecular tool for detecting pathogens in infections.
Provides fast results for clinical syndromes with minimal training.
People of Curetis
Unlock access to complete
Unlock access to complete
Funding Insights of Curetis
Curetis has successfully raised a total of $127.14M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $409.68 thousand completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Curetis
Curetis has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Qiagen, OpGen and European Investment Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe
|
Locked | Locked | Locked | |
|
Venture capital firm focused on lifescience and healthcare sectors
|
Locked | Locked | Locked |
Investor details for Curetis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Curetis
Investment portfolio details for Curetis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Curetis
Detailed financials for Curetis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Curetis Comparisons
Peer comparison for Curetis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Curetis
Curetis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prenetics, Inflammatix, Karius, Day Zero Diagnostics and MeMed, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| Locked | Locked | Locked |
Genome sequencing diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| Locked | Locked | Locked |
Portable PCR diagnostics for infectious diseases are developed.
|
Detailed competitors of Curetis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Curetis
Complete news archive for Curetis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Curetis
Curetis was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Curetis is headquartered in Holzgerlingen, Germany. It is registered at Holzgerlingen, Baden-wurttemberg, Germany.
Raju Jha is the current CEO of Curetis.
Curetis is a funded company, having raised a total of $127.14M across 14 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Curetis is 55.
The company was founded in 2007 in Holzgerlingen, Germany, and operates in the molecular diagnostics sector. A platform for detecting infectious diseases through multiparameter PCR testing is developed, targeting bacterial infections in hospitalized patients. The Unyvero A50 System is utilized with various cartridges to identify pathogens and resistance genes for conditions like pneumonia and implant infections, with results obtained in 4-5 hours.
Curetis's top competitors include Visby Medical, Inflammatix and Prenetics.
Curetis offers Unyvero and Unyvero A50 Solution.
Curetis has 13 investors. Key investors include Qiagen, OpGen, European Investment Bank, KfW, and BMBF.